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Abstract
Background: Bevacizumab is a humanized monoclonal antibody to human vascular endothelial cell growth factor
(VEGF) and has been used for many types of cancers such as colorectal cancer, non-small cell lung cancer, breast
cancer, and glioblastoma. Bevacizumab might be effective against gastric cancer, because VEGF has been reported
to be involved in the development of gastric cancer as well as other cancers. On the other hand, there are no
established biomarkers to predict the bevacizumab efficacy in spite of clinical needs. Therefore, we tried to identify
the predictive markers for efficacy of bevacizumab in gastric cancer patients by using bevacizumab-sensitive and
insensitive tumor models.
Methods: Nine human gastric and two colorectal cancer mouse xenografts were examined for their sensitivity to
bevacizumab. We examined expression levels of angiogenic factors by ELISA, bioactivity of VEGF by
phosphorylation of VEGFR2 in HUVEC after addition of tumor homogenate, tumor microvessel density by CD31-
immunostaining, and polymorphisms of the VEGF gene by HybriProbe™ assay.
Results: Of the 9 human gastric cancer xenograft models used, GXF97, MKN-45, MKN-28, 4-1ST, SC-08-JCK, and
SC-09-JCK were bevacizumab-sensitive, whereas SCH, SC-10-JCK, and NCI-N87 were insensitive. The sensitivity of
the gastric cancer model to bevacizumab was not related to histological type or HER2 status. All tumors with high
levels of VEGF were bevacizumab-sensitive except for one, SC-10-JCK, which had high levels of VEGF. The reason
for the refractoriness was non-bioactivity on the phosphorylation of VEGFR2 and micro-vessel formation of VEGF,
but was not explained by the VEGF allele or VEGF165b. We also examined the expression levels of other
angiogenic factors in the 11 gastrointestinal tumor tissues. In the refractory models including SC-10-JCK, tumor
levels of another angiogenic factor, bFGF, were relatively high. The VEGF/bFGF ratio correlated more closely with
sensitivity to bevacizumab than with the VEGF level.
Conclusions: VEGF levels and VEGF/bFGF ratios in tumors were related to bevacizumab sensitivity of the
xenografts tested. Further clinical investigation into useful predictive markers for bevacizumab sensitivity is
warranted.
Background
Vascular endothelial growth factor (VEGF), a diffusible
glycoprotein produced by normal and neoplastic cells, is
an important regulator of physiologic and pathologic
angiogenesis. Increased VEGF levels in serum or tumor
tissue have been reported to correlate with poor survi-
val; therefore, efficacy of anti-VEGF therapy is expected
in clinical application [1,2].
Bevacizumab is a humanized monoclonal antibody to
human VEGF that inhibits VEGF-mediated angiogenesis
in many types of tumors. In the US and EU, bevacizumab
is used in combination with standard chemotherapies for
patients with colorectal cancer, non-small cell lung cancer,
breast cancer, and glioblastoma. Although bevacizumab
improves progression-free survival (PFS) in these cancers,
it is not effective for all patients. Predictive markers of bev-
acizumab efficacy have been assessed in many clinical
trials [3], however, no validated biomarker is available to
predict bevacizumab efficacy and identify the patients who
could benefit from bevacizumab. Therefore, it is important
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the phase of clinical development for other cancer types.
Gastric cancer is one of the most malignant cancers
and second leading cause of cancer death in the world
[4]. The incidence is reportedly highest in Asia, South
America, and Southern Europe [5]. Increased levels of
VEGF expression have been found in gastric cancers as
well as in tumors of lung, breast, thyroid, gastrointestinal
tract, kidney, bladder, ovary, cervix, and pancreas, angio-
sarcomas and glioblastomas [6,7]. A previous report sug-
gests the possibility of VEGF as a prognostic factor of
gastric cancer [8]. Therefore, bevacizumab may also be
effective against gastric cancers [9]. In the present study,
the relationship between the efficacy of bevacizumab,
selected biomarkers in gastric cancers and various histo-
logical types of gastric cancer has been examined.
Methods
Test agents
Bevacizumab was provided by F. Hoffman-La Roche
(Nutley, NJ, USA) as a liquid and diluted with saline.
Human immunoglobulin G (HuIgG) was purchased from
MP Biomedicals, Inc. (Aurora, OH, USA) and was recon-
stituted with water and diluted with saline.
Animals
Male 5-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1
< nu >/CrlCrlj nu/nu) were obtained from Charles River
Japan (Yokohama, Japan). All animals were allowed to
acclimatize and recover from shipping-related stress for 1
week prior to the study. The health of the mice was mon-
itored by daily observation. Chlorinated water and irra-
diated food were provided ad libitum, and the animals
were kept in a controlled light-dark cycle (12 h-12 h).
Animal procedures were approved by the Institutional
Animal Care and Use Committee at Chugai Pharmaceu-
tical Co., Ltd..
Cell lines and culture conditions
Nine human gastric cancer cell lines and two human col-
orectal cancer cell lines were used in the present study.
MKN-45 and MKN-28 were purchased from Immuno-
Biochemical Laboratories Co., Ltd. (Fujioka, Japan). NCI-
N87, SCH, and HUVEC were obtained from the American
Type Culture Collection (Rockville, MD, USA), the Japan
Health Science Foundation (Osaka, Japan), and KURABO
(Osaka, Japan), respectively. MKN-45 was maintained in
TIL Media medium (Immuno-Biochemical Laboratories)
supplemented with 10% (v/v) FBS, and MKN-28, NCI-
N87, and SCH were maintained in RPMI-1640 supple-
mented with 10% (v/v) FBS at 37°C under 5% CO2.
HUVEC was maintained in HuMedia-EG2 (KURABO) at
37°C under 5% CO2. Cell lines 4-1ST, SC-08-JCK, SC-09-
JCK, SC-10-JCK and COL-16-JCK were purchased from
the Central Institute for Experimental Animals (Yoko-
hama, Japan). GXF97 and CXF280 were kindly provided
by Prof. H. H. Fiebig (University of Freiberg, Freiberg, Ger-
many). 4-1ST, SC-08-JCK, SC-09-JCK, SC-10-JCK, GXF97
and CXF280 were maintained in BALB/c-nu/nu mice by
subcutaneous (sc) inoculation of pieces of the tumor
tissue.
In vivo tumor growth inhibition studies
Each mouse was inoculated sc into the right flank with
either 5 × 10
6 cells/mouse of human gastric cancer cell
line MKN-45, MKN-28, NCI-N87 or SCH, or an 8-mm
3
piece of 4-1ST, SC-08-JCK, SC-09-JCK, SC-10-JCK,
GXF97 or CXF280 tumor tissue. Several weeks after
tumor inoculation, the mice were randomly allocated to
control and treatment groups. The administration of
anticancer agents was started when tumor volumes
reached approximately 0.2 to 0.3 cm
3.T oe v a l u a t et h e
antitumor activity of the test agents, tumor volume and
body weight were measured twice a week. Tumor volumes
(V) were estimated from the equation V = ab
2/2, where a
and b are tumor length and width, respectively. The per-
centage of tumor growth inhibition (TGI%) was calculated
as described previously [10].
Treatment of animals
Bevacizumab was administered intraperitoneally (ip)
once a week for 3 weeks.
Histological classification by hematoxylin-eosin staining
Xenograft tumor tissues were collected, formalin-fixed,
and paraffin-embedded. Slide specimens were prepared by
sectioning the tissue and staining with hematoxylin-eosin
stain. The histological classification was determined
according to the Japanese Classification of Gastric Carci-
noma (13th Edition, June 1999, Japanese Gastric Cancer
Association).
IHC, and gene amplification of HER2
HER2 protein expression and HER2 gene amplification
in tumors were examined by IHC using HercepTest
®
and FISH using Pathvysion
® respectively as described
previously [11].
Measurement of microvessel density in tumor tissues
Microvessel density (MVD) in tumor tissue was evaluated
immunohistochemically using a monoclonal anti-mouse
CD31 antibody (rat anti-mouse CD31 monoclonal anti-
body, clone MEC 13.3; BD Biosciences, NJ, USA). Tumor
samples were collected 24 h, 96 h or 21 days after bevaci-
zumab administration. Immunohistochemical staining
was performed as described previously [12]. MVD (%)
was calculated from the ratio of the CD31-positive stain-
ing area to the total observation area in the viable region.
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2 each) were
randomly analyzed, excluding necrotic areas. Positive
staining areas were calculated using imaging analysis
software (Win Roof; Mitani Corporation, Fukui, Japan).
Quantification of human or mouse VEGF and other
angiogenic proteins in tumor tissues and mouse serum
Blood and tumor samples were taken when tumors had
reached a volume of approximately 0.3 to 0.5 cm
3.B l o o d
serum was immediately retrieved and tumors were
immediately frozen in liquid nitrogen and stored at -80°
C. Tumor samples were homogenized in PBS containing
0.05% Tween 20 and centrifuged (4°C, 10,000 × g,
20 min.). The resultant supernatant was used for the
assays. Human VEGF, placental growth factor (PlGF),
interleukin-8 (IL-8) and basic fibroblast growth factor
(bFGF) were quantified using Quantikine
® ELISA kits
(R&D Systems, Minneapolis, MN, USA). Human
VEGF165b was quantified using the DuoSet
® ELISA
Development System (R&D Systems). Mouse VEGF was
quantified using a Mouse VEGF Assay Kit (Immuno-
Biochemical Laboratories). Total protein levels in the
samples were quantified using a DC protein assay kit
(BioRad Laboratories, Hercules, CA, USA).
VEGF genotyping
DNA was extracted from the cultured cells. VEGF poly-
morphisms (-2578, -1154, -634 and 936 on VEGF geno-
mic DNA) were genotyped with two fluorescent
hybridization probes using LightCycler™ software.
Briefly, the analysis is based on PCR amplification of the
region surrounding the polymorphism sites, followed by
slowly melting off the polymorphism-covering hybridized
probe while continuously detecting the fluorescence.
Melting off the hybridized probe from its target sequence
causes the fluorescent signal to disappear, and this allows
a narrow and reproducible estimation of the melting-
point temperature. Subtle differences in melting points
between a completely matched hybrid duplex and a
duplex with a single nucleotide mismatch are detectable
using LightCycler.
HUVEC pVEGFR2 assay
Tumor samples were homogenized in HuMedia-EB2
(KURABO) and centrifuged (4°C, 10,000 × g, 20 min). The
supernatant was retrieved and used as the assay medium.
VEGF concentration in the samples was measured as
described above. HUVEC was seeded at a density of 3 ×
10
5 cells/well into 6-well plates in HuMedia-EG2 and
incubated for 1 day at 37°C under 5% CO2. After that, the
medium was changed to a serum-starved medium (HuMe-
dia-EB2 containing 0.5% FBS). After overnight incubation,
the medium was changed to an assay medium which had
been pre-treated with bevacizumab or human IgG at 37°C
for 30 min. After 5-min incubation at 37°C under 5% CO2,
the plates were immediately placed on ice and the cells
washed with PBS. The cells were then lysed with ice-cold
lysis buffer #9 (R&D systems). Lysates were centrifuged at
14,000 × g for 20 min at 4°C. The pVEGFR2 was detected
using western blot method and DuoSet IC
® ELISA Devel-
opment System (R&D Systems). For western blot, antibo-
dies against VEGFR2 and pVEGFR2 (Tyr1175) (#2479 and
#2478 respectively, Cell Signaling Tschnology, Beverly,
MA, USA) were used as the first antibodies. The proteins
were detected by horseradish peroxidase-conjugated sec-
ondary antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and visualized using ECL plus (GE Healthcare
Life Science, Buckinghamshire, UK).
Statistical analysis
The statistical analysis was carried out using a SAS pre-
clinical package (SAS Institute, Inc., Tokyo, Japan).
Results
Sensitivity to bevacizumab in human gastric cancer
xenograft models
We examined the antitumor activity of bevacizumab in the
MKN-45 human gastric xenograft model. Bevacizumab
showed significant antitumor activity against MKN-45
tumors at doses ranging from 1.25 mg/kg to 20 mg/kg
(Figure 1A). On day 22 (21 days after starting treatment),
tumor growth inhibition rates (TGI%) were 62%, 76%, and
79% at doses of 1.25, 5, and 20 mg/kg, respectively. The
maximum effective dose was 5 mg/kg. Then we investi-
gated 5 mg/kg of bevacizumab antitumor activity against
human gastric cancer xenografts of various degrees of dif-
ferentiation as shown in Figure 1B. Bevacizumab showed
significant antitumor activity in GXF97, MKN-28, 4-1ST,
SC-08-JCK and SC-09-JCK, with TGI% values on day 22
of 78%, 56%, 68%, 75%, and 55%, respectively. Meanwhile,
bevacizumab did not show significant antitumor activity in
NCI-N87, SCH and SC-10-JCK, with TGI% values on day
22 of 21%, 3% and 11%, respectively (Figure 1C). We also
tested the antitumor activity of bevacizumab against two
colorectal tumors, COL-16-JCK and CXF280, as the con-
trol because bevacizumab is approved for clinical use in
colorectal cancers, and we found the TGI% to be 59% and
40%, respectively (Figure 1D). The degree of antitumor
activity of bevacizumab in the gastric cancer models was
comparable to that in the colorectal cancer models. No
weight loss (> 20%) was observed for any of the doses
tested in either model (data not shown).
Histological types of tumor tissues
The degree of differentiation among the tumors was
examined by using hematoxylin-eosin staining (Figure 1B).
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Figure 1 Antitumor activity of bevacizumab as a single agent in human gastric cancer xenograft models.( A) Mice bearing MKN-45
tumors were randomly divided into groups and HuIgG or bevacizumab (1.25, 5, 20 mg/kg) was administered intraperitoneally, once a week for
3 weeks. □: human IgG 20 mg/kg, ●: bevacizumab1.25 mg/kg, ■: bevacizumab 5 mg/kg, ▲: bevacizumab 20 mg/kg. (B) Differentiation degree of
each tumor was determined by hematoxylin-eosin staining. (C) Antitumor activity of bevacizumab (5 mg/kg) was evaluated in various types of
gastric cancer xenograft models: GXF97, MKN-28, NCI-N87, 4-1ST, SCH, SC-08-JCK, SC-09-JCK, SC-10-JCK. □: human IgG 20 mg/kg, ■: bevacizumab
5 mg/kg. (D) Antitumor activity of bevacizumab (5 mg/kg) was evaluated in two colorectal cancer xenograft models, COL-16-JCK and CXF280. □:
human IgG 20 mg/kg, ■: bevacizumab 5 mg/kg. Data points are mean + SD of tumor volume (mm
3). Statistically significant differences were
shown as *: P < 0.05 vs. control group by Wilcoxon test. (n = 5-7/group).
Yamashita-Kashima et al. BMC Cancer 2012, 12:37
http://www.biomedcentral.com/1471-2407/12/37
Page 4 of 11GXF97, MKN-28, SC-09-JCK, and NCI-N87 were categor-
ized as tubular adenocarcinoma, known as a well differen-
tiated type. MKN-45, 4-1ST and SCH were categorized as
poorly-differentiated adenocarcinoma and all of them
were solid-type. SC-08-JCK and SC-10-JCK were categor-
ized as signet-ring cell carcinoma. There was no correla-
tion between the efficacy of bevacizumab and the degree
of differentiation of the tumors, and bevacizumab showed
antitumor activity against every differentiation type of
tumor we tested as shown in Figure 1.
HER2 status of tumor tissues
HER2 status of tumor tissues which we examined beva-
sizumab sensitivity was shown in Table 1. There was
also no relevancy between the efficacy of bevacizumab
and the HER2 status, as shown by the observation that
the HER2-positive tumor 4-1ST was sensitive to bevaci-
zumab but HER2-positive tumors NCI-N87, and SCH
were insensitive to bevacizumab.
Expression of human VEGF
There is a possibility that the level of expression of human
VEGF in tumor tissue is involved in the efficacy of bevaci-
zumab, because bevacizumab is an anti-human VEGF
monoclonal antibody. We quantified the expression level
of human VEGF and VEGF165b in several gastric and col-
orectal tumor tissues (Figure 2A). We found that human
VEGF was hardly expressed in bevacizumab-insensitive
tumors SCH and NCI-N87 but, in the insensitive tumor
SC-10-JCK, human VEGF was expressed. VEGF165b is
reported to be an anti-angiogenic factor [13] and thus,
could inhibit bevacizumab activity. However, it was not
expressed to any extent in thet u m o r sw ei n v e s t i g a t e d .
Therefore, the effect of VEGF165b was considered to be
negligible in the examined tumor models. Angiogenic
human VEGF was more significantly expressed in bevaci-
zumab-sensitive tumors compared with bevacizumab-
insensitive tumors (Figure 2B, p = 0.0485). The correlation
coefficient (r
2) between TGI% and the log concentration
of human VEGF per mg protein in tumor tissue was
0.5312. We also quantified the expression level of mouse
VEGF in the tumors, but the correlation coefficient
Table 1 HER2 expression in gastrointestinal cancer cell
lines
HER2 status
Cell line IHC FISH
NCI-N87 2+ 8.4
4-1ST 3+ 5.3
SCH 2+ 2.0
SC-09-JCK 0 1.2
SC-10-JCK 0 1.2
MKN-45 0 1.1
MKN-28 0 1.0
SC-08-JCK 0 1.0
GXF97 0 0.9
HER2 protein expression and HER2 gene amplification in tumors were
examined by IHC using HercepTest
® and FISH using Pathvysion
® respectively
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Figure 2 Expression of human VEGF proteins in tumor tissues of
gastric and colorectal cancer xenograft models.( A) The level of
human VEGF (black bar) and VEGF165b (open bar) protein in
bevacizumab-sensitive and bevacizumab-insensitive tumor tissues was
quantified by ELISA (n =4 / g r o u p ) .( B) The quantity of VEGF was
compared between the two groups. The averages were shown as bars
and numeric values. *: P < 0.05 vs. sensitive group by Wilcoxon test.
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Page 5 of 11between TGI% and mouse tumor VEGF was not observed
(r
2 = 0.0098). We also quantified human and mouse VEGF
in serum, but the level of expression was below the limit of
detection (< 31.25 pg/mL).
Polymorphisms of VEGF
In clinical breast cancer patients, the efficacy of bevacizu-
mab is reported to correlate to the status of VEGF poly-
morphism, the -2578A allele. Hence, we tried to examine
the correlation of VEGF polymorphisms and efficacy, but
statistical analysis could not be done because the A/A
allele was only observed in the MKN-45 tumor. The level
of VEGF in MKN-45 was not high, even though the -2578
allele exists in the VEGF promoter (Table 2).
Bioactivity of VEGF in SC-10-JCK
We examined whether the VEGF expressed in SC-10-
JCK was bioactive. Tumor tissue lysates of two bevacizu-
mab-sensitive models, GXF97 (high VEGF expression)
and 4-1ST (VEGF level equivalent to SC-10-JCK), and
one bevacizumab-insensitive model, SC-10-JCK, with or
without bevacizumab, were added to HUVEC, and the
phosphorylation level of VEGFR2 in HUVEC was tested
by western blot (Figure 3A). VEGF levels of the lysates
of GXF97, 4-1ST and SC-10-JCK were 24.7, 8.0 and 4.7
ng/mL respectively. VEGF derived from bevacizumab-
sensitive tumors (GXF97 and 4-1ST) phosphorylated
VEGFR2. The VEGF diluted to 4.7 ng/mL (a concentra-
tion equal to SC-10-JCK-derived VEGF) still phosphory-
lated VEGFR2. All phosphorylation of VEGFR2 by
VEGF from bevacizumab-sensitive tumors was reduced
by bevacizumab. On the other hand, SC-10-JCK-derived
VEGF did not phosphorylate VEGFR2 both in western
blot and ELISA (Figure 3B). These results suggest that
the VEGF in SC-10-JCK was not bioactive.
Anti-angiogenic activity of bevacizumab
We also examined changes in MVD in bevacizumab-sensi-
tive and -insensitive tumors after bevacizumab treatment
using CD31-staining (Figure 4A). In the bevacizumab-
sensitive tumor models, GXF97 and SC-08-JCK, a signifi-
cant decrease of MVD was observed at 96 h after single-
treatment of bevacizumab and at 21 days after the 3-week
treatment (Figure 4B and 4C). On the other hand, MVD
had not changed at any time point after bevacizumab
treatment in the bevacizumab-insensitive tumor models,
SC-10-JCK and SCH (Figure 4D and 4E). The decrease of
MVD was corresponded to the antitumor activity of beva-
cizumab, but was detected earlier than the decrease of
tumor volume (Figure 4F-I). We also examined the change
in MVD in the GXF97 tumor samples at the lower dose (1
mg/kg), at which bevacizumab had not shown efficacy on
day 22 (Figure 4J). In correlation with the efficacy of beva-
cizumab, MVD had not changed in GXF97 tumor tissue
96 h after bevacizumab treatment at the low dose. There-
fore we considered that bevacizumab showed antitumor
activity by inhibiting tumor angiogenesis.
Table 2 VEGF polymorphisms in gastrointestinal cancer
cell lines
Genotype
Polymorphic site
Cell line -2578 -1154 -634 936
MKN-45 A/A A/A G/G T/T
4-1ST C/A G/A G/G C/C
GXF97 C/A G/A C/G C/C
MKN-28 C/C G/A C/C C/C
SC-09-JCK C/C G/A G/G C/C
SC-08-JCK C/C G/A C/C T/T
NCI-N87 C/A G/A G/G C/C
SC-10-JCK C/A G/A G/G C/T
SCH C/C G/A C/G C/C
VEGF polymorphisms (-2578, -1154, -634 and 936 on VEGF genomic DNA)
were examined by using LightCycler™
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Figure 3 Differences in the bioactivity of human VEGF in
bevacizumab-sensitive tumors and bevacizumab-insensitive
tumor SC-10-JCK. The bioactivity of VEGF in tumors was
determined by the VEGFR2 phosphorylation of HUVEC treated with
tumor tissue homogenate administered with bevacizumab or
human IgG using western blot (A) and ELISA (B). Each VEGF level in
the homogenate was shown in Figure 3A and B.
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Figure 4 Change in MVD after bevacizumab treatment.( A) CD31 immunostaining in tumor tissue at 96 h after treated with HuIgG (Ctrl) and
bevacizumab (BV) in GXF97, SC-08-JCK, SC-10-JCK and SCH models. (B-E) The MVD in tumor tissue was determined by calculating the ratio of
CD31-immunostaining positive area to the total observation area at 24 h, 96 h and 21 days (21 d) after bevacizumab treatment (n = 3-6/group).
(F-I) Tumor volumes were measured on the day of MVD evaluation. (J) MVD after treatment of bevacizumab at 1 mg/kg was evaluated in GXF97
(n = 4). *: P < 0.05 vs. control group by Wilcoxon test.
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factor in tumor tissues
The MVD results after bevacizumab treatment suggested
that angiogenic factors other than VEGF are involved in
angiogenesis in bevacizumab-insensitive tumors. There-
fore, we investigated the expression levels of angiogenic
factors bFGF, IL-8 and PlGF in tumor tissues, all of
which are reported to be angiogenic factors for tumors
(Table 3). Each one as a single factor did not significantly
correlate with bevacizumab efficacy (Figure 5A). How-
ever, the VEGF/bFGF ratio in bevacizumab-insensitive
tumors was significantly lower than that in bevacizumab-
sensitive tumors (1.30% vs. 12.4%, Figure 5B, p = 0.0242).
Discussion
Gastric cancer has long been classified according to
degree of differentiation and histopathologic type.
Recently, HER2 expression has been included as a classi-
fication method in response to the positive results of a
phase III study showing that addition of trastuzumab to a
combination of capecitabine (or 5FU) and CDDP in
patients with HER2-overexpressing gastric cancers pro-
longed overall survival [14]. In light of this, we attempted
to clarify the types of gastric cancers for which bevacizu-
mab would be effective. We used human cancer xeno-
graft models developed by inoculating human gastric
cancer cells into T-cell-deficient mice to investigate the
efficacy of bevacizumab. Human VEGF secreted from
human cancer cells is known to have an effect on mouse
endothelial cells and results in angiogenesis in xenograft
tumor tissues. In MKN-45, bevacizumab showed signifi-
cant antitumor activity, although the dose dependency
was not strong. A low dose of bevacizumab (1.25 mg/kg)
was sufficient to produce antitumor activity. We exam-
ined the antitumor activity of bevacizumab in 9 human
gastric cancer xenograft models of various degrees of dif-
ferentiation, tumor types, and HER2 expression.
However, the sensitivity of the gastric cancer models to
bevacizumab was found to be unrelated to the histologi-
cal type or the HER2 status of the tumors. The antitumor
activity of bevacizumab in the gastric cancer xenograft
models was similar to that observed in colorectal cancer
[15], for which bevacizumab has shown survival and clin-
ical benefit.
Next, we examined other biomarker candidates of beva-
cizumab efficacy using sensitive and insensitive gastric
tumor models. Because VEGF is the molecular target of
bevacizumab, the tumor level of VEGF is thought to influ-
ence the sensitivity to bevacizumab. Tumor VEGF levels
were significantly lower in the xenograft models insensi-
tive to bevacizumab than in the sensitive models; however,
mouse tumor VEGF showed no differences between sensi-
tive and insensitive tumors. Human and mouse blood
VEGF were lower than the detection limit in these models,
and thus they were of littlec o n c e r n .I nt h eS C - 1 0 - J C K
model, in spite of VEGF expression, bevacizumab did not
exhibit efficacy. To clarify the role of VEGF as a biomarker
candidate of bevacizumab sensitivity, we investigated sub-
types of VEGF in more detail. Various isoforms of VEGF
are known such as the reportedly anti-angiogenic VEGF,
VEGF165b [13]. VEGF165b binds to bevacizumab [16]. In
our study, VEGF165b exhibited 100% cross-reactivity to
VEGF ELISA (data not shown) so we thought that
VEGF165b expression would be high in SC-10-JCK. How-
ever, the level of VEGF165b was low in the SC-10-JCK
model. Additionally, VEGF165b expression was low in all
of the tumor tissues we examined. In the gastrointestinal
models tested, VEGF165b is not a concern. Because beva-
cizumab binds to all angiogenic isoforms of VEGF, such as
VEGF121, VEGF165, and VEGF189 [17], identification of
these isoforms is not necessary. In clinical breast cancer
treatment, polymorphisms of VEGF have been found to
correlate with the efficacy of the bevacizumab and pacli-
taxel combination [18]. The survival time of patients with
Table 3 Expression of angiogenic factors in gastrointestinal cancer cell lines
Cell line Sensitivity to bevacizumab VEGF PlGF IL-8 bFGF
COL-16-JCK + 4430 ± 991 < 15.6 360 ± 171 268 ± 75.3
SC-08-JCK + 2330 ± 402 < 15.6 < 31.3 145 ± 25.9
GXF97 + 1950 ± 753 < 15.6 362 ± 134 107 ± 63.6
MKN-45 + 1560 ± 310 < 15.6 65.9 ± 9.38 183 ± 43.0
CXF280 + 1480 ± 290 < 15.6 < 31.3 77.6 ± 16.5
SC-09-JCK + 1020 ± 163 < 15.6 165 ± 60.3 151 ± 13.3
4-1ST + 706 ± 106 < 15.6 < 31.3 87.7 ± 5.47
MKN-28 + 577 ± 285 16.4 ± 8.22 < 31.3 200 ± 27.8
SC-10-JCK - 760 ± 80.2 < 15.6 198 ± 96.5 231 ± 105
NCI-N87 - 171 ± 52.5 < 15.6 34.4 ± 10.8 1090 ± 328
SCH - < 31.3 1210 ± 205 < 31.3 38.4 ± 18.6
Mean ± SD (pg/mg protein)
The expression of human VEGF, PlGF, IL-8 and bFGF in tumor tissues were examined by ELISA
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Page 8 of 11the 2578 AA allele or 1154 A allele of VEGF was longer
than that of others. However, VEGF 2578 and 1154 of SC-
10-JCK were CA and GA, respectively, and the type of
allele was the same as with the sensitive tumors 4-1ST and
GXF97. The VEGF allele did not distinguish sensitivity to
bevacizumab in these models. Next, to clarify whether the
VEGF of SC-10-JCK had biological activity, the effect of a
tumor homogenate of SC-10-JCK on the induction of
VEGFR phosphorylation on HUVEC was examined. The
tumor homogenate of SC-10-JCK did not have phosphory-
lation activity in contrast to that of 4-1ST or GXF97.
Furthermore, the MVD in the SC-10-JCK xenograft model
treated with bevacizumab was not reduced, indicating that
the VEGF of SC-10-JCK did not show angiogenic activity.
These results suggest the possibility of existence of non-
active VEGF in tumors.
We attempted to clarify both the biomarker for and the
mechanisms of bevacizumab. The inhibition of MVD in
tumor tissue is reported to be a major mechanism of beva-
cizumab efficacy, and so we compared MVD inhibition
with efficacy in bevacizumab-sensitive and -insensitive
tumor models. The existence of MVD inhibition corre-
sponded with antitumor efficacy. In the present study, the
MVD inhibition prior to antitumor efficacy was shown,
and MVD inhibition was found to be a mechanism of bev-
acizumab efficacy. Our results indicated that other angio-
genic factors except for VEGF are involved in biomarkers
for bevacizumab resistance. We examined tumor bFGF,
IL-8 and PlGF, all of which are reported to be angiogenic
factors for tumors [19-21]. When we compared the ratio
of bFGF to VEGF with bevacizumab efficacy to clarify the
extent of the role of VEGF in angiogenesis, the ratio of
VEGF to bFGF in bevacizumab-insensitive tumors was
clearly lower than that in bevacizumab-sensitive tumors.
It is thought that an intimate cross-talk of bFGF and
VEGF family is exist during angiogenesis and bFGF
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Figure 5 Expression of human bFGF protein in tumor tissues of gastric and colorectal cancer xenograft models.( A) The level of human
bFGF, PlGF, and IL-8 proteins in tumor tissues sensitive (9 models) or insensitive (3 models) to bevacizumab was quantified by ELISA (n = 4).
Open circle means less than the detection limit of ELISAs. The averages were shown as bars and numeric values. (B) The ratio of VEGF to bFGF
was compared between the two groups. *: P < 0.05 vs. sensitive group by Wilcoxon test.
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Page 9 of 11increases neuroplin-1, a co-receptor for VEGF, expression
in human vascular smooth muscle cell that in turn
enhance the effect of VEGF on cell migration and promote
neovascularizaion [22]. In the present study, we did not
examine the bioactivity of bFGF in the bevacizumab insen-
sitive tumors. It is necessary to investigate the effect of
bFGF on VEGF-dependent angiogenesis and on its inhibi-
tion by bevacizumab in the future. Neither VEGF/PlGF
nor VEGF/IL-8 showed significant results (data not
shown). PlGF has been reported to form a homodimer or
heterodimer with VEGF and bind the resulting VEGFR in
angiogenesis [23]. However, the cell lines we examined did
not express PlGF, except for SCH, so we examined the
relationship between PlGF and bevacizumab in SCH in
vitro. HUVEC growth induction with a PlGF/VEGF het-
erodimer was inhibited by bevacizumab (data not shown),
suggesting that the number of heterodimers of PlGF and
VEGF would also be a biomarker for bevacizumab sensi-
tivity. Further examination is needed. PlGF homodimers
did not show HUVEC growth induction, and we did not
examine the effect of bevacizumab on HUVEC growth.
Some reports have indicated that bevacizumab exhibits
direct cell growth inhibition against tumor cells [24,25].
However, in the gastric cancer cell lines we examined,
no direct antitumor activity was observed in spite of the
growth inhibition shown by bevacizumab in the xeno-
graft model of the same cancer cell line (data not
shown).
Conclusions
In the present study of gastric cancer treatment, we found
that levels of VEGF and the VEGF/bFGF ratio have a close
correlation with sensitivity to bevacizumab in the tested
cell lines. There was no correlation between sensitivity to
bevacizumab and the histological classification according
to the degree of differentiation or HER2 status of the
tumor cells. Clinical evidence is expected.
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